Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Frontiers in Oncology|December 10, 2025
Management of ovarian granulosa cell tumor in childhood: a case report and recommendations for a multidisciplinary approachSofia Maria Carlotta Arnaboldi, Giovanna Gattuso, Maria Laura Nicolosi, et al.
Cancer Chemotherapy and Pharmacology|November 7, 2020
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patientsMarina Macchini, Umberto Peretti, Giulia Orsi, et al.
Clinical and Translational Radiation Oncology|May 23, 2024
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinomaPaolo Passoni, Michele Reni, Sara Broggi, et al.
Scientific Reports|September 5, 2020
Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer patientsNajla Slim, Paolo Passoni, Elena Incerti, et al.
Nuclear Medicine Communications|August 1, 2019
Early variation of 18-fluorine-labelled fluorodeoxyglucose PET-derived parameters after chemoradiotherapy as predictors of survival in locally advanced pancreatic carcinoma patientsElena Incerti, Emilia G Vanoli, Sara Broggi, et al.
Annals of Surgical Oncology|January 13, 2012
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trialMichele Reni, Gianpaolo Balzano, Giuseppe Aprile, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 18, 2020
Predicting pathological response after radio-chemotherapy for rectal cancer: Impact of late oxaliplatin administrationSara Broggi, Paolo Passoni, Calogero Gumina, et al.
Cancers|March 28, 2025
Temporal Validation of an FDG-PET-Radiomic Model for Distant-Relapse-Free-Survival After Radio-Chemotherapy for Pancreatic AdenocarcinomaMonica Maria Vincenzi, Martina Mori, Paolo Passoni, et al.
International Journal of Radiation Oncology, Biology, Physics|December 7, 2025
Incorporating Individual Early Response in the Dose-Effect Relationship of Complete Pathological Response Following Neoadjuvant Radiochemotherapy for Rectal CancerAlessandro Cicchetti, Martina Mori, Paolo Passoni, et al.
The Lancet. Oncology|June 1, 2005
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trialMichele Reni, Stefano Cordio, Carlo Milandri, et al.
Pageof 6